| 000 | 04486naaaa2201261uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/61309 | ||
| 005 | 20220714154420.0 | ||
| 020 | _abooks978-3-03928-759-8 | ||
| 020 | _a9783039287598 | ||
| 020 | _a9783039287581 | ||
| 024 | 7 |
_a10.3390/books978-3-03928-759-8 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 100 | 1 |
_aCheung, Kwok-Leung _4auth _91564800 |
|
| 245 | 1 | 0 | _aTreatment Strategies and Survival Outcomes in Breast Cancer |
| 260 |
_bMDPI - Multidisciplinary Digital Publishing Institute _c2020 |
||
| 300 | _a1 electronic resource (264 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aTreatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by-nc-nd/4.0/ _2cc _4https://creativecommons.org/licenses/by-nc-nd/4.0/ |
||
| 546 | _aEnglish | ||
| 653 | _arelative survival | ||
| 653 | _ayoung women | ||
| 653 | _acancer treatment | ||
| 653 | _an/a | ||
| 653 | _afulvestrant | ||
| 653 | _alapatinib | ||
| 653 | _atumor biology | ||
| 653 | _aantihormone therapy | ||
| 653 | _amastectomy | ||
| 653 | _aaromatase inhibitors | ||
| 653 | _achemotherapy | ||
| 653 | _aserum biomarker | ||
| 653 | _acyclin E | ||
| 653 | _aanthracycline resistance | ||
| 653 | _azero-inflated Poisson regression model | ||
| 653 | _alymph-node ratio | ||
| 653 | _aCHEK2 | ||
| 653 | _acomparative effectiveness | ||
| 653 | _abreast-conserving therapy | ||
| 653 | _ataxane sensitivity | ||
| 653 | _aliquid biopsy | ||
| 653 | _aHER2 c-erbB2 | ||
| 653 | _acolorectal cancer | ||
| 653 | _ainfiltrating breast cancer | ||
| 653 | _asurvival | ||
| 653 | _aexercise characteristics | ||
| 653 | _alactate dehydrogenase | ||
| 653 | _abiomarker | ||
| 653 | _abreast cancer survivors | ||
| 653 | _aBRCA | ||
| 653 | _adisease-free survival | ||
| 653 | _aPIK3CA | ||
| 653 | _ametastatic breast cancer | ||
| 653 | _acell-free DNA | ||
| 653 | _ainvasive breast cancer | ||
| 653 | _aradiotherapy | ||
| 653 | _aMetformin | ||
| 653 | _asocial well-being | ||
| 653 | _agene expression | ||
| 653 | _acontralateral breast cancer | ||
| 653 | _abasal-like breast cancer | ||
| 653 | _aLMK-235 | ||
| 653 | _aSrc kinase | ||
| 653 | _aHER2/neu | ||
| 653 | _aLKB1 | ||
| 653 | _aOlder women | ||
| 653 | _aLDH | ||
| 653 | _amutation carriers | ||
| 653 | _astage IV | ||
| 653 | _amammography screening | ||
| 653 | _aNCDB | ||
| 653 | _acMet | ||
| 653 | _aSEER | ||
| 653 | _apertuzumab | ||
| 653 | _aphysical function | ||
| 653 | _aoutcome | ||
| 653 | _aribociclib | ||
| 653 | _aolder patients | ||
| 653 | _ageriatric oncology | ||
| 653 | _ametastatic | ||
| 653 | _aoverdiagnosis | ||
| 653 | _anext-generation sequencing | ||
| 653 | _aabemaciclib | ||
| 653 | _aEndocrine therapy | ||
| 653 | _amonitoring metastatic breast cancer | ||
| 653 | _abreast cancer | ||
| 653 | _acirculating tumor cells | ||
| 653 | _aBreast Cancer | ||
| 653 | _aPALB2 | ||
| 653 | _ahistone deacetylase | ||
| 653 | _aprognosis | ||
| 653 | _aphysical activity | ||
| 653 | _atrastuzumab | ||
| 653 | _aductal carcinoma in situ | ||
| 653 | _acontralateral prophylactic mastectomy | ||
| 653 | _aERCC1 | ||
| 653 | _afamily history | ||
| 653 | _aT-DM1 | ||
| 653 | _aATM | ||
| 653 | _aadvanced breast cancer | ||
| 653 | _aincidence | ||
| 653 | _apalbociclib | ||
| 653 | _aHDAC5 inhibitors | ||
| 653 | _aAPOBEC3B | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://mdpi.com/books/pdfview/book/2255 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/61309 _70 _zDOAB: description of the publication |
| 999 |
_c2974167 _d2974167 |
||